Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for XEN1120 (Kv7 channel opener) in Pain. The expected timing is based on the latest available company guidance and may change.
5/12/25- CTA accepted. Ph1 initiation in 2025. 11/03/25:- Phase 1 SAD/MAD study underway in healthy adults. 02/26/26:- XEN1120 Phase 1 SAD/MAD in healthy adults ongoing; completion expected in 2026 to support Phase 2 pain study. 05/07/26:- XEN1120 Phase 1 SAD/MAD pain study ongoing; completion expected in H2 2026 to support Phase 2 proof-of-concept. 08/06/26:- XEN1120 Phase 1 SAD/MAD completion remains expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.